Amber Therapeutics raises $100M in a series A funding round to develop bio e-stim for urinary incontinence therapy
Amber Therapeutics raises $100M in a series A funding round to develop bio e-stim for urinary incontinence therapy
06/11/24, 5:08 AM
Location
londonMoney raised
$100 million
Industry
therapeutics
biotechnology
health care
Amber Therapeutics Ltd. has raised $100 million in a series A funding round to further develop its implantable closed-loop bioelectrical therapy to treat women suffering from mixed urinary incontinence. The financing is one of the largest series A rounds ever seen in Europe’s medical technology space.
Company Info
Location
london, england, united kingdom
Additional Info
Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need. We have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation.
Amber UI is the company’s first therapy, aiming to restore normal physiological function in women suffering with mixed urinary incontinence.